Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

Vinay Prasad, Victoria Kaestner, Sham Mailankody

Research output: Contribution to journalShort surveypeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers'. Together they form a unique fingerprint.